Cargando…
A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases
Verinurad, a uric acid transporter 1 (URAT1) inhibitor, lowers serum uric acid by promoting its urinary excretion. Co-administration with a xanthine oxidase inhibitor (XOI) to simultaneously reduce uric acid production rate reduces the potential for renal tubular precipitation of uric acid, which ca...
Autores principales: | Leander, Jacob, Sunnåker, Mikael, Rekić, Dinko, Aksenov, Sergey, Eriksson, Ulf G., Johansson, Susanne, Parkinson, Joanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225519/ https://www.ncbi.nlm.nih.gov/pubmed/33728547 http://dx.doi.org/10.1007/s10928-021-09747-y |
Ejemplares similares
-
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
por: Tan, Philip K., et al.
Publicado: (2017) -
Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
por: Stack, Austin G, et al.
Publicado: (2020) -
Individualized treatment strategies for hyperuricemia informed by a semi‐mechanistic exposure‐response model of uric acid dynamics
por: Aksenov, Sergey, et al.
Publicado: (2018) -
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
por: Smith, William B., et al.
Publicado: (2018) -
Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)